Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 14/20 | 0.49 |
| ▸ | MAOA | P21397 | 10/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | SOD1 | P00441 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12949746 | 0.84 | NSD2 (0.71) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL15889565 | 0.84 | NSD2 (0.71) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL1003510 | 0.84 | NSD2 (0.71) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL136664 | 0.83 | NSD2 (1.00) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL15111341 | 0.83 | NSD2 (0.70) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL119148 | 0.83 | NSD2 (0.69) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL14151016 | 0.81 | NSD2 (0.63) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL3477099 | 0.80 | NSD2 (0.66) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL154969 | 0.80 | NSD2 (0.54) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL94424 | 0.79 | NSD2 (0.52) | NSD2ABL1PPARGRIN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286193-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2020-05-27 | — | — | EP | disclosed |
| EP-3286193-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2018-02-28 | — | — | EP | disclosed |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| WO-2016166684-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2016-10-20 | — | — | WO | disclosed |
| US-9365540-B2 | Benzimidazole derivatives as MCH receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| WO-2009120655-A1 | INDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009103478-A1 | PYRIDONE AND PYRIDAZINONE DERIVATIVES AS MCH ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009103478-A1 | PYRIDONE AND PYRIDAZINONE DERIVATIVES AS MCH ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009089482-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090137587-A1 | Phenylpyridone Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | MCHR1, MCHR2, MC1R | NSD2 3876/4885ABL1 1976/4885PPARG 985/4885 |
| US-20090137587-A1 | Phenylpyridone Derivative | NAT1, NPR1, PC | NSD2 882/4885ABL1 3032/4885PPARG 304/4885 |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | NSD2 3647/4885ABL1 1074/4885PPARG 172/4885 |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | NSD2 2048/4885ABL1 2355/4885PPARG 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.